基于铁代谢指标、营养状态探究促红细胞生成素联合铁剂治疗人类免疫缺陷病毒阳性肾损害透析贫血患者的临床效果  

Exploration of the clinical effect of erythropoietin combined with iron therapy on human immunodeficiency virus-positive patients with renal damage and dialysis anemia based on iron metabolism indicators and nutritional status

作　　者：欣怡 XIN Yi(Department of Hemodialysis,Chengdu Public Health Clinical Medical Center,Chengdu 610000,Sichuan,China)

机构地区：[1]成都市公共卫生临床医疗中心血液透析科,成都610000

出　　处：《中国性科学》2024年第7期145-149,共5页Chinese Journal of Human Sexuality

基　　金：2022年成都市医学科研课题立项项目(2022456)。

摘　　要：目的探究促红细胞生成素联合铁剂治疗人类免疫缺陷病毒(HIV)阳性肾损害透析贫血患者的临床效果。方法选取2016年8月至2022年12月成都市公共卫生临床医疗中心收治的102例HIV阳性肾损害透析贫血患者作为研究对象。依据治疗方法不同分为对照组和研究组,每组51例。两组均行常规治疗,在此基础上,对照组接受促红细胞生成素治疗,研究组接受促红细胞生成素联合铁剂治疗。比较两组的治疗效果、不良反应发生情况、治疗前后红细胞计数(RBC),以及降钙素原(PCT)、铁蛋白(SF)、白蛋白(Alb)、红细胞平均体积(MCV)、白介素-6(IL-6)、血清铁(SI)、血红蛋白(Hb)水平。结果研究组治疗总有效率显著高于对照组(P<0.05);治疗6周、12周后,研究组RBC、MCV、Hb、SF、Alb、SI高于对照组,IL-6、PCT低于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论促红细胞生成素联合铁剂治疗HIV阳性肾损害透析贫血患者的疗效好,可有效调控炎症介质及铁代谢,进而改善患者的贫血症状。Objective To explore the clinical effect of erythropoietin combined with iron therapy on human immunodeficiency virus(HIV)-positive patients with renal damage and dialysis anemia.Methods A total of 102 HIV-positive patients with renal damage and dialysis anemia treated in Chengdu Public Health Clinical Medical Center from August 2016 to December 2022 were selected as the research subjects.They were divided into a control group and a study group according to different treatment methods,with 51 cases in each group.Both groups received conventional treatment,and on this basis,the control group received erythropoietin treatment,while the study group received erythropoietin combined with iron therapy.The treatment effects and adverse reactions occurrence of the two groups were compared,as well as the levels of red blood cell count(RBC),procalcitonin(PCT),ferritin(SF),albumin(Alb),mean corpuscular volume(MCV),interleukin-6(IL-6),serum iron(SI),hemoglobin(Hb)before and after treatment.Results The total effective rate of the study group was significantly higher than that of the control group(P<0.05).After 6 and 12 weeks of treatment,the study group had higher RBC,MCV,Hb,SF,Alb,and SI than the control group,and lower IL-6 and PCT than the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions The efficacy of erythropoietin combined with iron in the treatment of HIV-positive patients with renal damage and dialysis anemia is good,which can effectively regulate inflammatory mediators and iron metabolism,thereby improve the patient′s anemia symptoms.

关 键 词：人类免疫缺陷病毒阳性 肾损害 透析 贫血 促红细胞生成素 铁剂 

分 类 号：R759[医药卫生—皮肤病学与性病学]